Drug Manufacturers - Other

The launch of Victoza should help inject further growth into Novo's lucrative diabetes franchise.

We don't see value in Arena following the FDA panel's negative recommendation.

Buoyed by diverse operations, we expect Bayer will post steady growth over the next 10 years.

The FDA may find it politically impossible to approve ATI - 7505 , ARYx's derivative of previously recalled cisapride , no matter how well it is tested . Reformulating dangerous drugs , like cisapride and warfarin , require more onerous testing and may result in unintended adverse events . The

Hospitals may believe that Entereg has an unfavorable risk-reward profile given the cardiovascular events that occurred with long-term use, which could negatively affect sales of the drug.Entereg is a first-in-class therapeutic. Hospitals may be wary of adding a new drug to their formulary or want

Switching costs for drug-eluting stents are low for end users, which could prove extremely detrimental to Angiotech if another crisis emerges around its paclitaxel-based platform.Angiotech's new products may not succeed for many reasons, including regulatory rulings or delays, tepid demand from

Shire is emerging beyond generic Adderall XR with a portfolio of high-growth products.

Life insurance and related service markets are highly competitive and inherently unstable places to attempt to produce superior shareholder returns.Aegon's management hasn't proved a reliable steward of shareholder value, and it remains headed by one of the key senior executives leading the company